Medication info
Sitagliptin 50 mg Tablet (Sitagliptin Hydrochloride Hydrate)

Sitagliptin 50 mg Tablet (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
A light apricot-colored, biconvex round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTPX2]
Approval status
Active

MFDS item code 202101404 · Approved 2021.02.18 · Insurance code 657807910

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This drug is administered once daily at a dose of 100 mg as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medicine is used with diet and exercise to help patients with type 2 diabetes control their blood sugar. It can be administered alone for patients beginning treatment, and when monotherapy does not sufficiently control blood sugar, it is used in combination with metformin. Additionally, it can be added to treatment when sufficient control is difficult with sulfonylurea, thiazolidinedione, or insulin monotherapy. This drug enhances therapeutic effects even when blood sugar control is inadequate despite combination therapy with multiple medications. It is flexibly used in various cases to improve blood sugar control.

Dosage and Administration

Adult dosage

This drug is administered once daily at a dose of 100 mg as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Precautions

This medicine may cause severe hypersensitivity reactions after administration, so if allergic symptoms occur, discontinue use immediately. Consult a physician immediately if symptoms of pancreatitis appear while taking the medication, and discontinue use if necessary. Patients with type 1 diabetes or hypersensitivity to any component of this drug should not take it. Patients with decreased kidney function need to adjust the dosage, so consult a physician. When used in combination with other hypoglycemic agents, caution is needed due to the risk of hypoglycemia, and dosage adjustments of other medications may be necessary. Prolonged use may lead to adverse reactions such as arthralgia, skin rash, and blistering skin diseases, so inform a physician if symptoms occur. Pregnant or breastfeeding women are advised to avoid taking this medication. Elderly patients should undergo regular kidney function tests as kidney function may decline. In case of overdose, immediate medical attention is required, and some removal may be possible through hemodialysis. This drug has little effect on cardiovascular safety, but it is important to consult healthcare professionals if adverse reactions occur.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative dermatitis
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infections
  • nasopharyngitis
  • headache
Show 30 more
  • diarrhea
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe arthralgia with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent air or moisture from entering and should be kept at room temperature between 1 and 30 degrees Celsius. This helps maintain the efficacy of the drug and prevents degradation.

Appearance and packaging

Appearance

A light apricot-colored, biconvex round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTPX2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.